Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 3 Summary of overall survival by Kaplan–Meier

Published byIndra Kartawijaya Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 3 Summary of overall survival by Kaplan–Meier"— Presentation transcript:

1 Figure 3 Summary of overall survival by Kaplan–Meier
analysis across seminal clinical trials in patients with advanced-stage melanoma Figure 3 | Summary of overall survival by Kaplan–Meier analysis across seminal clinical trials in patients with advanced-stage melanoma. The clinical trials that have defined modern clinical care of patients with advanced-stage melanoma are shown with colour-coding to identify each study. The BRF113220, COMBI-d, COMBI-v and CoBRIM trials were performed only in patients with BRAFV600E/K-mutant melanoma. Median and landmark overall survival outcomes have been improved with both BRAF-directed treatment and immunotherapy approaches. n, number of patients treated. Luke, J. J. et al. (2017) Targeted agents and immunotherapies: optimizing outcomes in melanoma Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "Figure 3 Summary of overall survival by Kaplan–Meier"

Similar presentations

What should patients with BRAF mutant melanoma receive as front line therapy? Antoni Ribas, M.D. Professor of Medicine Professor of Surgery Professor of.

What should patients with BRAF mutant melanoma receive as front line therapy? Antoni Ribas, M.D. Professor of Medicine Professor of Surgery Professor of.
The Nurse View: Management of Pancreatic Cancer

The Nurse View: Management of Pancreatic Cancer
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Figure 2 Response after initial increase in total tumour burden

Figure 2 Response after initial increase in total tumour burden
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer
Figure 1 Concept of the therapeutic index

Figure 1 Concept of the therapeutic index
Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.
Figure 2 Multiscale modelling in oncology

Figure 2 Multiscale modelling in oncology
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 3 Monitoring clonal evolution using liquid biopsies
Figure 3 Molecular subgroups of glioblastoma,

Figure 3 Molecular subgroups of glioblastoma,
Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Similar presentations

Ads by Google